Robotic Endovascular Surgery Systems in 2025: Transforming Minimally Invasive Vascular Procedures and Accelerating Global Market Expansion. Explore the Next Wave of Precision, Automation, and Clinical Impact.

Executive Summary: Key Trends and Market Highlights for 2025
Market Size, Growth Rate, and Forecast (2025–2030)
Technological Innovations: Robotics, AI, and Imaging Integration
Competitive Landscape: Leading Companies and Strategic Initiatives
Clinical Applications and Efficacy in Vascular Interventions
Regulatory Environment and Reimbursement Trends
Adoption Drivers: Hospital Demand, Surgeon Training, and Patient Outcomes
Challenges: Technical Barriers, Cost, and Workflow Integration
Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets
Future Outlook: Next-Generation Systems, Partnerships, and Market Opportunities
Sources & References

Executive Summary: Key Trends and Market Highlights for 2025

The landscape of robotic endovascular surgery systems is poised for significant transformation in 2025, driven by rapid technological advancements, expanding clinical adoption, and strategic investments from leading medtech companies. These systems, designed to enhance precision, reduce radiation exposure, and improve patient outcomes in minimally invasive vascular procedures, are increasingly being integrated into major hospitals and specialized cardiovascular centers worldwide.

A key trend for 2025 is the continued evolution and commercialization of next-generation robotic platforms. Corindus, A Siemens Healthineers Company remains a frontrunner with its CorPath GRX system, which has received regulatory clearances in multiple regions and is being utilized for complex coronary and peripheral vascular interventions. Siemens Healthineers is actively investing in expanding the system’s capabilities, including remote operation and integration with advanced imaging modalities, aiming to further reduce procedure times and improve operator ergonomics.

Another major player, Hansen Medical, continues to develop its Magellan Robotic System, focusing on peripheral vascular and neurovascular applications. The company is expected to announce new software upgrades and partnerships in 2025, targeting improved navigation and real-time feedback for interventionalists. Meanwhile, Intuitive Surgical, renowned for its da Vinci robotic platform, is reportedly exploring expansion into the endovascular space, leveraging its expertise in robotic-assisted surgery and data-driven procedural analytics.

The market is also witnessing the entry of innovative startups and regional manufacturers, particularly in Asia and Europe, who are developing cost-effective and compact robotic solutions tailored for emerging markets. This diversification is anticipated to accelerate global adoption, especially as healthcare systems seek to address the growing burden of cardiovascular disease with scalable, high-precision technologies.

From a regulatory and reimbursement perspective, 2025 is expected to see further clarity and support for robotic endovascular procedures, with ongoing clinical trials and real-world evidence contributing to broader acceptance by payers and providers. Industry bodies such as the Society of Interventional Radiology are actively involved in establishing best practices and training standards, ensuring safe and effective integration of robotics into clinical workflows.

Looking ahead, the outlook for robotic endovascular surgery systems is robust, with double-digit market growth projected over the next few years. Key drivers include the rising prevalence of vascular diseases, increasing demand for minimally invasive interventions, and the ongoing convergence of robotics, artificial intelligence, and digital health platforms. As leading companies and new entrants continue to innovate, 2025 is set to be a pivotal year for the adoption and evolution of robotic endovascular technologies.

Market Size, Growth Rate, and Forecast (2025–2030)

The global market for robotic endovascular surgery systems is poised for significant expansion between 2025 and 2030, driven by technological advancements, increasing adoption in interventional cardiology and neurovascular procedures, and a growing emphasis on minimally invasive techniques. As of 2025, the market is characterized by a handful of pioneering companies, ongoing clinical validation, and a rising number of regulatory approvals in major healthcare markets.

Key industry players include Corindus, A Siemens Healthineers Company, which offers the CorPath GRX system—currently the only FDA-cleared robotic platform for percutaneous coronary and peripheral vascular interventions. Siemens Healthineers continues to invest in expanding the clinical applications and geographic reach of its robotic portfolio. Another notable company is Hansen Medical, now part of Auris Health, which has developed the Magellan Robotic System for endovascular navigation, though its primary focus has shifted toward robotic bronchoscopy. Intuitive Surgical, while best known for the da Vinci system in soft tissue surgery, is also exploring applications in vascular interventions.

In 2025, the global market size for robotic endovascular surgery systems is estimated to be in the range of several hundred million USD, with North America and Europe representing the largest regional markets due to early adoption and favorable reimbursement environments. The Asia-Pacific region is expected to demonstrate the fastest growth, propelled by increasing healthcare investments and a rising burden of cardiovascular and neurovascular diseases.

Market growth rates are projected to be robust, with compound annual growth rates (CAGR) commonly cited in the low to mid-teens through 2030. This expansion is underpinned by several factors:

Continued clinical evidence supporting improved precision, reduced radiation exposure, and enhanced procedural outcomes with robotic assistance.
Broader regulatory clearances for new indications, including neurovascular and peripheral vascular interventions.
Strategic partnerships between device manufacturers and hospital networks to accelerate adoption and training.
Ongoing R&D investments by leading companies such as Siemens Healthineers and Intuitive Surgical to expand system capabilities and reduce costs.

Looking ahead to 2030, the market outlook remains highly positive. The integration of artificial intelligence, improved haptic feedback, and remote operation capabilities are expected to further drive adoption. As more clinical data emerges and cost-effectiveness is demonstrated, robotic endovascular surgery systems are likely to become a standard of care in high-volume centers worldwide.

Technological Innovations: Robotics, AI, and Imaging Integration

Robotic endovascular surgery systems are at the forefront of technological innovation in minimally invasive cardiovascular and neurovascular interventions. As of 2025, the integration of robotics, artificial intelligence (AI), and advanced imaging is rapidly transforming procedural precision, operator safety, and patient outcomes. The sector is characterized by a handful of pioneering companies, each advancing the capabilities and adoption of these systems.

One of the most established players is Corindus, A Siemens Healthineers Company, whose CorPath GRX system is the first FDA-cleared robotic platform for percutaneous coronary and peripheral vascular interventions. The system enables physicians to perform procedures remotely from a radiation-shielded workstation, reducing radiation exposure and enhancing procedural accuracy through robotic-assisted device manipulation. In 2024, Corindus announced ongoing clinical studies and collaborations to expand the system’s applications into neurovascular interventions, with expectations for broader regulatory clearances and commercial rollouts in the next few years.

Another significant innovator is Robocath, a French company whose R-One robotic platform is CE-marked for coronary angioplasty. Robocath’s system leverages advanced haptic feedback and precise device control, and the company is actively developing next-generation platforms that integrate AI-driven decision support and real-time imaging fusion. In 2025, Robocath is expected to initiate multi-center clinical trials across Europe and Asia, aiming to validate the safety and efficacy of its technology in complex vascular procedures.

Emerging companies such as Endovascular Technologies and Sensome are also contributing to the field. Endovascular Technologies is developing robotic systems with enhanced navigation for neurovascular interventions, while Sensome focuses on AI-powered micro-sensors that can be integrated with robotic catheters to provide real-time tissue characterization during stroke treatment.

A key trend in 2025 is the convergence of robotics with advanced imaging modalities, such as 3D rotational angiography and intravascular ultrasound, enabling real-time visualization and navigation. Companies are also exploring the use of AI algorithms for automated lesion detection, device selection, and procedural planning, which could further reduce operator variability and improve outcomes.

Looking ahead, the next few years are expected to see increased adoption of robotic endovascular systems in both high-volume centers and community hospitals, driven by growing clinical evidence, expanded indications, and improved cost-effectiveness. Strategic partnerships between device manufacturers, imaging companies, and AI developers are likely to accelerate the pace of innovation, with the ultimate goal of enabling fully remote, teleoperated interventions and expanding access to advanced vascular care worldwide.

Competitive Landscape: Leading Companies and Strategic Initiatives

The competitive landscape for robotic endovascular surgery systems in 2025 is characterized by rapid technological advancements, strategic partnerships, and a growing number of regulatory milestones. The sector is led by a handful of pioneering companies, each leveraging proprietary technologies to address the increasing demand for precision, safety, and efficiency in minimally invasive vascular interventions.

Corindus, a Siemens Healthineers Company, remains a dominant force in the field. Its flagship CorPath GRX system is the first and only FDA-cleared robotic platform for both percutaneous coronary and peripheral vascular interventions. Since its acquisition by Siemens Healthineers in 2019, Corindus has benefited from Siemens’ global reach and integration with advanced imaging and digital health solutions. In 2024 and into 2025, Corindus has focused on expanding clinical applications, including neurovascular procedures, and has announced collaborations with major hospital networks to further validate remote and telerobotic capabilities.

Robocath, a French medtech innovator, has made significant strides with its R-One robotic platform, which is CE-marked for coronary angioplasty. The company has accelerated its international expansion, particularly in Europe and Asia, and is actively pursuing regulatory clearance in the United States. In 2025, Robocath is expected to launch next-generation systems with enhanced haptic feedback and AI-driven navigation, following successful clinical trials and strategic partnerships with leading academic centers.

Intuitive Surgical, renowned for its da Vinci robotic systems in other surgical domains, has signaled its intent to enter the endovascular space. While not yet commercialized as of early 2025, Intuitive Surgical has invested in R&D and filed patents related to vascular robotics, suggesting future competition and potential disruption in the market.

Other notable players include Hansen Medical, which has a history in intravascular robotics, and Smith+Nephew, which is exploring robotic-assisted vascular access as part of its broader digital surgery portfolio. Startups and spin-offs from academic institutions are also emerging, often focusing on AI integration, remote operation, and cost-effective solutions tailored for outpatient settings.

Strategic initiatives across the sector include cross-industry collaborations, investments in telemedicine-enabling features, and the pursuit of expanded regulatory indications. As reimbursement frameworks evolve and clinical evidence mounts, the competitive landscape is expected to intensify, with established leaders and new entrants vying for market share in a rapidly growing global market.

Clinical Applications and Efficacy in Vascular Interventions

Robotic endovascular surgery systems are increasingly being integrated into clinical practice for vascular interventions, with 2025 marking a period of accelerated adoption and clinical validation. These systems, designed to enhance precision, stability, and operator ergonomics, are being utilized in a range of procedures including percutaneous coronary interventions (PCI), peripheral vascular interventions (PVI), and neurovascular interventions.

One of the most prominent systems in this field is the CorPath platform, developed by Siemens Healthineers following its acquisition of Corindus Vascular Robotics. The CorPath GRX system is FDA-cleared for both coronary and peripheral vascular procedures, and ongoing clinical studies in 2024–2025 are expanding its indications. Early data from multi-center registries and single-center experiences suggest that robotic-assisted PCI can reduce radiation exposure to operators by up to 95% and improve procedural accuracy, particularly in complex cases such as chronic total occlusions and bifurcation lesions. The system’s remote capabilities are also being explored for potential telerobotic interventions, which could address disparities in access to specialized care.

In the neurovascular domain, Sensome and Stryker are developing and evaluating robotic platforms for stroke thrombectomy and aneurysm coiling. While most neurovascular robotic interventions remain in early clinical or preclinical phases, pilot studies in 2024–2025 are demonstrating feasibility and safety, with the potential to standardize complex maneuvers and reduce operator fatigue. These advances are particularly relevant as the demand for neurointerventional procedures grows with an aging population.

Peripheral vascular interventions are also benefiting from robotic assistance. Siemens Healthineers and Intuitive Surgical are both investing in research and development for next-generation systems capable of navigating tortuous anatomy and deploying devices with sub-millimeter precision. Early clinical feedback highlights improved device control and the potential for reduced contrast usage, which is significant for patients with renal impairment.

Looking ahead, the clinical efficacy of robotic endovascular systems is expected to be further substantiated by large-scale randomized controlled trials and real-world registries in 2025 and beyond. Key areas of focus include long-term patient outcomes, cost-effectiveness, and the integration of artificial intelligence for enhanced procedural planning and intraoperative guidance. As regulatory approvals expand and more hospitals adopt these technologies, robotic endovascular surgery is poised to become a standard of care in complex vascular interventions.

Regulatory Environment and Reimbursement Trends

The regulatory environment for robotic endovascular surgery systems is evolving rapidly as these technologies gain traction in interventional cardiology, neurovascular, and peripheral vascular procedures. In 2025, the U.S. Food and Drug Administration (FDA) continues to play a pivotal role, with several systems already cleared for specific indications. For example, the Corindus, A Siemens Healthineers Company CorPath GRX system is FDA-cleared for percutaneous coronary and peripheral vascular interventions, and ongoing clinical studies are expected to support expanded indications, including neurovascular applications. The European Union, under the Medical Device Regulation (MDR), maintains a similarly rigorous but distinct pathway, with CE marking required for market entry. Companies such as Abbott and Siemens Healthineers are actively navigating these regulatory frameworks to broaden their portfolios.

In Asia, regulatory agencies in Japan and China are increasingly receptive to robotic-assisted vascular interventions, with local manufacturers and global players seeking approvals. For instance, MicroPort is developing robotic systems tailored to regional needs, and is working with the National Medical Products Administration (NMPA) in China for market authorization.

Reimbursement remains a critical factor influencing adoption. In the United States, the Centers for Medicare & Medicaid Services (CMS) currently reimburses for endovascular procedures based on existing Current Procedural Terminology (CPT) codes, regardless of whether the procedure is performed robotically or manually. However, there is growing advocacy from industry stakeholders, including Intuitive Surgical and Siemens Healthineers, for the establishment of add-on payments or new codes that recognize the unique value and potential cost savings of robotic systems, such as reduced radiation exposure and improved procedural precision.

In Europe, reimbursement policies vary by country, with some national health systems beginning to pilot bundled payments or technology-specific incentives for robotic interventions. The United Kingdom’s National Health Service (NHS) and Germany’s statutory health insurance system are both evaluating the cost-effectiveness of robotic endovascular procedures, which could influence broader adoption in the coming years.

Looking ahead, the regulatory and reimbursement landscape is expected to become more favorable as clinical evidence accumulates and health technology assessment bodies recognize the benefits of robotic endovascular surgery. Industry leaders are actively engaging with regulators and payers to shape policies that support innovation while ensuring patient safety and value for healthcare systems.

Adoption Drivers: Hospital Demand, Surgeon Training, and Patient Outcomes

The adoption of robotic endovascular surgery systems is accelerating in 2025, driven by a confluence of hospital demand, evolving surgeon training paradigms, and a growing body of evidence supporting improved patient outcomes. Hospitals are increasingly seeking advanced robotic platforms to address the rising complexity of endovascular procedures, the need for precision, and the imperative to reduce occupational hazards for staff. Leading manufacturers such as Corindus, A Siemens Healthineers Company and Hansen Medical (now part of Auris Health, itself acquired by Johnson & Johnson) are at the forefront, offering systems designed for coronary, peripheral, and neurovascular interventions.

A key driver for hospital adoption is the potential for robotic systems to reduce radiation exposure for both patients and clinicians. Traditional endovascular procedures require prolonged fluoroscopy, exposing operators to cumulative radiation and orthopedic strain from lead aprons. Robotic platforms, such as the CorPath GRX by Corindus, enable remote operation from shielded workstations, addressing these occupational health concerns. Hospitals are also motivated by the potential for increased procedural accuracy and reproducibility, which can translate into fewer complications and shorter procedure times.

Surgeon training is evolving in tandem with technology adoption. Robotic endovascular systems require a new skill set, blending traditional catheterization expertise with proficiency in robotic controls and digital interfaces. Manufacturers are investing in comprehensive training programs, simulation platforms, and proctoring to accelerate the learning curve. For example, Corindus offers structured training pathways and virtual reality modules to support credentialing and ongoing education. This focus on training is critical, as hospitals seek to ensure that staff can fully leverage the capabilities of these advanced systems.

Patient outcomes remain a central consideration. Early and ongoing clinical studies suggest that robotic-assisted endovascular procedures can achieve at least equivalent, and in some cases superior, outcomes compared to manual techniques. Benefits include enhanced precision in device placement, reduced risk of vascular injury, and the potential for more consistent results across operators. As more data emerges from multicenter registries and post-market surveillance, hospitals are increasingly confident in the safety and efficacy profile of these systems.

Looking ahead, the outlook for robotic endovascular surgery systems is robust. As hospitals continue to prioritize staff safety, procedural efficiency, and patient outcomes, demand for these technologies is expected to grow. Ongoing innovation from industry leaders such as Corindus and Johnson & Johnson (via its Auris Health subsidiary) will likely expand the range of treatable conditions and further integrate robotics into mainstream vascular care.

Challenges: Technical Barriers, Cost, and Workflow Integration

Robotic endovascular surgery systems are at the forefront of minimally invasive cardiovascular and neurovascular interventions, but their widespread adoption faces several significant challenges as of 2025 and looking ahead. The primary barriers include technical limitations, high costs, and the complexities of integrating these systems into existing clinical workflows.

Technical Barriers: Despite rapid advancements, current robotic endovascular platforms still face limitations in haptic feedback, device compatibility, and system dexterity. Many systems, such as the Corindus, A Siemens Healthineers Company CorPath GRX, offer remote manipulation of guidewires and catheters but lack the nuanced tactile sensation that experienced interventionalists rely on for complex procedures. This can hinder the adoption of robotics for challenging cases, such as chronic total occlusions or intricate neurovascular interventions. Additionally, device compatibility remains a hurdle, as not all commercially available catheters and wires are approved or optimized for use with robotic systems, limiting procedural versatility.

Cost Considerations: The initial capital investment for robotic endovascular systems is substantial, often exceeding several hundred thousand dollars per unit, with ongoing maintenance and disposable costs adding to the financial burden. For example, the CorPath GRX system’s acquisition and operational expenses can be prohibitive for many hospitals, especially those in resource-constrained settings. Reimbursement models for robotic-assisted procedures are still evolving, and in many regions, there is no additional compensation for using robotic technology, making it challenging for healthcare providers to justify the investment without clear evidence of improved outcomes or efficiency.

Workflow Integration: Integrating robotic systems into established catheterization laboratories and operating rooms requires significant changes in workflow, staff training, and infrastructure. The learning curve for operators and support staff can be steep, necessitating dedicated training programs and simulation. Furthermore, the physical footprint of robotic systems, such as those from Siemens Healthineers and Vesalio, may require modifications to existing facilities. Ensuring seamless interoperability with imaging systems and electronic health records is another ongoing challenge, as is maintaining procedural efficiency during the transition period.

Looking forward, industry leaders are investing in next-generation platforms with improved haptics, broader device compatibility, and enhanced integration capabilities. However, overcoming these technical, economic, and workflow barriers will be critical for the broader adoption of robotic endovascular surgery systems in the coming years.

Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets

The global landscape for robotic endovascular surgery systems is rapidly evolving, with significant regional differences in adoption, regulatory environment, and market growth. As of 2025, North America, Europe, and Asia-Pacific represent the primary markets, while emerging economies are beginning to show increased interest and investment in these advanced surgical technologies.

North America remains the leading region for robotic endovascular surgery systems, driven by high healthcare expenditure, advanced hospital infrastructure, and a strong focus on minimally invasive procedures. The United States, in particular, is home to key innovators such as Corindus, A Siemens Healthineers Company, which has developed the CorPath GRX system—one of the first FDA-cleared robotic platforms for percutaneous coronary and peripheral vascular interventions. The region benefits from a favorable regulatory environment and robust clinical research activity, with numerous hospitals integrating robotic systems into their cardiovascular suites. Canada is also witnessing gradual adoption, supported by government initiatives to modernize healthcare technology.

Europe is experiencing steady growth, propelled by increasing demand for precision medicine and a rising burden of cardiovascular diseases. Countries such as Germany, the United Kingdom, and the Netherlands are at the forefront, with leading academic centers and hospitals participating in clinical trials and early adoption programs. The European Union’s regulatory framework, while stringent, has facilitated the entry of CE-marked robotic systems. Companies like Abbott and Philips are active in the region, collaborating with local partners to expand the reach of their endovascular robotics portfolios.

Asia-Pacific is emerging as a high-growth market, fueled by large patient populations, rising healthcare investments, and increasing awareness of minimally invasive techniques. China and Japan are leading the region, with government support for medical innovation and a growing number of hospitals adopting robotic-assisted vascular interventions. Local manufacturers are also entering the field, aiming to address regional needs and cost sensitivities. For example, MicroPort Scientific Corporation is developing and commercializing robotic systems tailored for Asian healthcare settings. India and South Korea are also showing momentum, with pilot programs and public-private partnerships accelerating adoption.

Emerging markets in Latin America, the Middle East, and Africa are at an earlier stage, but interest is rising as healthcare infrastructure improves and the benefits of robotic endovascular surgery become more widely recognized. Adoption is currently limited to major urban centers and private hospitals, but international collaborations and technology transfer initiatives are expected to drive gradual market entry over the next few years.

Looking ahead, regional disparities in reimbursement, training, and infrastructure will continue to shape the pace of adoption. However, ongoing innovation, regulatory harmonization, and increased investment are expected to support broader global uptake of robotic endovascular surgery systems through 2025 and beyond.

Future Outlook: Next-Generation Systems, Partnerships, and Market Opportunities

The landscape for robotic endovascular surgery systems is poised for significant transformation in 2025 and the following years, driven by rapid technological advancements, strategic partnerships, and expanding clinical adoption. The next generation of these systems is expected to deliver enhanced precision, improved workflow integration, and broader procedural capabilities, addressing both coronary and peripheral vascular interventions.

Key industry players are accelerating innovation. Corindus, A Siemens Healthineers Company continues to advance its CorPath GRX platform, focusing on expanding indications beyond percutaneous coronary interventions (PCI) to include neurovascular and peripheral vascular procedures. The company is also investing in remote robotic capabilities, aiming to enable telerobotic interventions—a development that could address specialist shortages in underserved regions and facilitate rapid response in acute cases such as stroke.

Meanwhile, Hansen Medical, now part of Auris Health (a subsidiary of Johnson & Johnson), is leveraging its Magellan Robotic System for complex endovascular navigation. The integration of advanced imaging, artificial intelligence, and haptic feedback is anticipated to further refine operator control and safety. These enhancements are expected to be incorporated into new product iterations and potentially into hybrid operating room environments.

Emerging companies are also entering the market. Robocath, based in France, is expanding its R-One robotic platform, with ongoing clinical studies in Europe and Asia. The company is actively pursuing partnerships with hospital networks and device manufacturers to accelerate adoption and regulatory approvals in new geographies. Similarly, Sensome is developing connected guidewire technologies that could synergize with robotic systems, providing real-time tissue characterization and feedback during interventions.

Strategic collaborations are shaping the sector’s future. Partnerships between robotic system manufacturers and major medical device companies—such as stent and catheter suppliers—are expected to streamline device compatibility and procedural efficiency. Additionally, alliances with telecommunication and cloud technology providers are being explored to support secure, real-time remote operation and data analytics.

Looking ahead, the market outlook is robust. The demand for minimally invasive vascular procedures is rising globally, driven by aging populations and increasing prevalence of cardiovascular disease. Regulatory agencies in the US, Europe, and Asia are actively engaging with manufacturers to establish clear pathways for approval of next-generation robotic systems. As a result, the coming years are likely to see broader clinical adoption, expanded procedural indications, and the emergence of fully integrated, AI-enabled robotic endovascular platforms.

Sources & References

Telerobotics for Endovascular Care | Grace Katzschmann, Nanoflex Robotics | WIRED Health

Watch this video on YouTube.

Robotic Endovascular Surgery Systems 2025: Revolutionizing Vascular Care with 18% CAGR Growth

ByQuinn Parker